EZH2 Inhibitor Scaffold Optimization for Selective Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EZH2 inhibitors are limited to clinical stages with no marketed products, necessitating the development of novel compounds with effective activity against EZH2-mediated diseases such as various cancers.
Innovation Solution
Development of a class of compounds represented by Formula (I) or its pharmaceutically acceptable forms, which act as EZH2 inhibitors, including specific heterocyclic and aromatic groups, to target EZH2 and treat EZH2-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current EZH2 inhibitors are developed through clinical stages, then their safety and efficacy are improved, but the time to market and development cost increase significantly
Solution Approach 1:
The patent performs preliminary biochemical screening and cellular activity testing early in the development process to identify promising compounds before committing to extensive clinical development, thereby reducing overall development time while maintaining safety and efficacy standards
Solution Approach 2:
The patent optimizes chemical structure parameters of EZH2 inhibitors to enhance binding affinity and selectivity, allowing for more effective compounds that may require less extensive clinical validation while maintaining safety profiles
2Reliability
If novel compound structures are designed for EZH2 inhibition, then their selectivity and activity are improved, but the complexity of synthesis and manufacturing increases
Solution Approach 1:
The patent divides the complex heterobicyclic structure into modular building blocks (pyridine ring, diazepine ring, indole ring, etc.) that can be synthesized separately and then assembled through standardized coupling reactions, reducing overall synthesis complexity while maintaining molecular selectivity
Solution Approach 2:
The patent designs versatile intermediate structures that can serve multiple purposes in different synthesis routes and can be adapted to generate various EZH2 inhibitor analogs, thereby simplifying the overall manufacturing process while maintaining high selectivity
3Adaptability or versatility
If diverse substituent groups are introduced in Formula (I), then the range of EZH2-mediated diseases treatable is expanded, but the number of compounds to screen and develop increases
Solution Approach 1:
The patent introduces specific substituent groups at particular positions (R1-R7) on the heterobicyclic core structure to target different disease mechanisms and biological pathways, allowing selective optimization for different EZH2-mediated diseases without requiring complete resynthesis of the entire molecule
Solution Approach 2:
The patent employs a core heterobicyclic structure that serves as a common scaffold for multiple drug candidates, with disease-specific functionality achieved through nested substituent groups, thereby reducing the total number of compounds needing development while expanding disease coverage
Data Source
AI summary
The present application provides a compound represented by formula (I), or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof; and a use thereof in preparing drugs used to treat EZH2-mediated disease.